SOLANA BEACH, Calif., July 01, 2024 (GLOBE NEWSWIRE) --Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding protein 5 (FABP5) inhibitor at the 34th Annual International Cannabinoid Research Society (ICRS) Symposium being held June 30 to July 5, 2024 in Salamanca, Spain..

加利福尼亚州索拉纳海滩，2024年7月1日（环球通讯社）--Artelo Biosciences，Inc.（纳斯达克：ARTL），一家临床阶段制药公司，专注于调节脂质信号通路，为患有癌症，疼痛，皮肤病和神经系统疾病的人开发治疗方法，今天宣布，Artelo转化科学副总裁Saoirse O'Sullivan教授在2024年6月30日至7月5日于西班牙萨拉曼卡举行的第34届国际大麻素研究学会（ICRS）年会议上介绍了与Artelo新型脂肪酸结合蛋白5（FABP5）抑制剂ART26.12相关的临床前数据。。

The presentation entitled, “ART26.12, a Novel Fatty Acid-Binding Protein 5 Inhibitor, Shows Efficacy in Breast Cancer-Induced Bone Pain,” highlights the effectiveness of ART26.12 in reducing pain behaviors induced by breast cancer in preclinical studies. This new data is from the fourth in a series of preclinical pain models that demonstrated similar activity with ART26.12.

题为“ART26.12，一种新型脂肪酸结合蛋白5抑制剂，在乳腺癌引起的骨痛中显示出疗效”的演讲强调了ART26.12在临床前研究中减轻乳腺癌引起的疼痛行为的有效性。这一新数据来自一系列临床前疼痛模型中的第四个，这些模型表现出与ART26.12相似的活性。

Specifically, effective doses and plasma exposures in the breast cancer bone pain study are consistent with previously published data of ART26.12 in oxaliplatin-induced peripheral neuropathy (https://www.jpain.org/article/S1526-5900(24)00345-6/fulltext)..

(https://www.jpain.org/article/S1526-5900（24）00345-6/全文）。。

“ART26.12 continues to deliver positive preclinical efficacy data to support its development as a novel non-opioid, non-steroidal analgesic treatment,” stated Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo. “We continue to be impressed with the consistent activity and efficacious dose levels of ART26.12 in multiple animal models of pain and painful neuropathies, whether caused by cancer, diabetes, or multiple chemotherapies.

Artelo转化科学副总裁Saoirse O'Sullivan教授表示：“ART26.12继续提供积极的临床前疗效数据，以支持其作为新型非阿片类非甾体镇痛药的发展。”。“我们仍然对ART26.12在多种疼痛和疼痛性神经病动物模型中的持续活性和有效剂量水平印象深刻，无论是由癌症，糖尿病还是多种化学疗法引起的。

We look forward to initiating human trials with ART26.12 subject to Artelo’s Investigational New Drug application acceptance by the U.S. Food and Drug Administration.”.

我们期待着在美国食品和药物管理局接受Artelo的研究性新药申请后，开始使用ART26.12进行人体试验。”。

Breast cancer, the most common cancer in women, spreads to bone more frequently than other parts of the body. More than half people with advanced stage breast cancer experience bone metastasis, often leading to debilitating pain, fractures, and spinal cord compression. ART26.12, Artelo’s potent and selective FABP5 inhibitor, represents a new approach to treating pain associated with cancer where few effective therapies with minimal adverse effects exist..

乳腺癌是女性最常见的癌症，比身体其他部位更容易扩散到骨骼。超过一半的晚期乳腺癌患者经历骨转移，通常会导致虚弱的疼痛，骨折和脊髓压迫。Artelo的强效和选择性FABP5抑制剂ART26.12代表了一种治疗癌症相关疼痛的新方法，其中几乎没有有效的治疗方法，不良反应最小。。

About ART26.12

关于ART26.12

Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids including endocannabinoids and fatty acids. FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies. ART26.12, Artelo’s lead FABP inhibitor, is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with initial clinical development planned for chemotherapy-induced peripheral neuropathy (CIPN).

脂肪酸结合蛋白（FABPs）是一类细胞内蛋白，可伴侣脂质，包括内源性大麻素和脂肪酸。FABP在许多病理学中过度表达并与异常脂质信号传导相关。Artelo的主要FABP抑制剂ART26.12是一种有效且选择性的FABP5抑制剂，被开发为一种新型的外周作用非阿片类非甾体镇痛药，最初的临床开发计划用于化疗引起的周围神经病（CIPN）。

ART26.12 and other proprietary compounds from Artelo’s extensive library of small molecule inhibitors of FABPs have shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, and anxiety disorders..

Artelo广泛的FABPs小分子抑制剂库中的ART26.12和其他专有化合物已显示出治疗某些癌症，神经性和伤害性疼痛以及焦虑症的治疗前景。。

About the International Cannabinoid Research Society

关于国际大麻素研究学会

The International Cannabinoid Research Society (ICRS) is the premier global scientific association with more than 650 international members from 40 countries, all active researchers in the field of endogenous, plant-derived, and synthetic cannabinoids and related bioactive lipids. In addition to acting as a source for impartial information on cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research.

国际大麻素研究学会（ICRS）是全球首屈一指的科学协会，有来自40个国家的650多名国际成员，他们都是内源性、植物源性和合成大麻素及相关生物活性脂质领域的活跃研究人员。除了作为有关大麻和大麻素的公正信息来源外，ICRS的主要作用是为研究人员提供一个开放的论坛，以会面和讨论他们的研究。

The ICRS Symposium is being held June 30- July 5, 2024 in Salamanca, Spain. Interested parties may follow @ICRS_Society on X. .

ICRS研讨会于2024年6月30日至7月5日在西班牙萨拉曼卡举行。感兴趣的各方可以在X上关注@ICRS\U Society。

About Artelo Biosciences

关于Artelo生物科学

Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, and inflammation.

Artelo Biosciences，Inc.是一家临床阶段制药公司，致力于开发和商业化专有疗法，该疗法可调节脂质信号传导途径，包括内源性大麻素系统。Artelo正在推出一系列广泛适用的候选产品，旨在解决多种疾病和病症（包括厌食症、癌症、焦虑症、疼痛和炎症）中未满足的重大需求。

Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio..

。更多信息请访问www.artelobio.com和推特：@artelobio。。

Forward Looking Statements

前瞻性声明

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature.

本新闻稿包含《1933年证券法》第27A节、《1934年证券交易法》第21E节和《私人证券诉讼改革法》修订版所指的某些前瞻性声明，包括与公司产品开发、临床和监管时间表、市场机会、竞争地位、可能或假定的未来经营成果、业务战略、潜在增长机会和其他具有预测性质的声明有关的前瞻性声明。

These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms.

这些前瞻性陈述基于当前对我们经营的行业和市场的期望、估计、预测和预测以及管理层当前的信念和假设。这些陈述可以通过使用前瞻性表达来识别，包括但不限于“期望”、“预期”、“打算”、“计划”、“相信”、“估计”、“潜力”、“预测”、“项目”、“应该”、“将会”以及类似的表达和这些术语的否定之处。

These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

这些报表与未来事件或我们的财务业绩有关，涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致实际结果、业绩或成就与前瞻性报表明示或暗示的任何未来结果、业绩或成绩存在重大差异。

Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release.

这些因素包括公司向证券交易委员会提交的文件中规定的因素，包括我们未来筹集额外资本的能力。警告潜在投资者不要过度依赖此类前瞻性声明，这些声明仅在本新闻稿发布之日起生效。

The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new.

公司没有义务公开更新任何前瞻性声明，无论是由于新的。

Investor Relations Contact:

投资者关系联系人：

Crescendo Communications, LLC

Crescendo通信有限责任公司

Tel: 212-671-1020

电话：212-671-1020

Email: ARTL@crescendo-ir.com

电子邮件ARTL@crescendo-ir.com